Filing Details

Accession Number:
0000921895-20-000958
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2020-03-31 18:34:40
Reporting Period:
2020-03-13
Accepted Time:
2020-03-31 18:34:40
Original Submission Date:
2020-03-27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
727510 Enzon Pharmaceuticals Inc. ENZN Biological Products, (No Disgnostic Substances) (2836) 222372868
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1265094 Jonathan Couchman 600 Fifth Avenue
2Nd Floor
New York NY 10020
No No Yes No
1459450 Myrexis, Inc. 600 Fifth Avenue, 2Nd Floor
New York NY 10020
No No No Yes
1571659 Xstelos Corp. 600 Fifth Avenue
2Nd Floor
New York NY 10020
No No No Yes
1737322 Fund Family Couchman 600 Fifth Avenue
2Nd Floor
New York NY 10020
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.01 Par Value Acquisiton 2020-03-13 19,709 $0.14 1,594,232 No 4 P Indirect By Xstelos Corp.
Common Stock, $0.01 Par Value Acquisiton 2020-03-23 2,678 $0.14 2,928 No 4 P Indirect By Myrexis, Inc.
Common Stock, $0.01 Par Value Acquisiton 2020-03-25 469,551 $0.14 472,479 No 4 P Indirect By Myrexis, Inc.
Common Stock, $0.01 Par Value Acquisiton 2020-03-26 160,785 $0.14 633,264 No 4 P Indirect By Myrexis, Inc.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Xstelos Corp.
No 4 P Indirect By Myrexis, Inc.
No 4 P Indirect By Myrexis, Inc.
No 4 P Indirect By Myrexis, Inc.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.01 Par Value 4,717,666 Direct
Common Stock, $0.01 Par Value 400,000 Indirect By Couchman Family Fund
Footnotes
  1. This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis" and, together with Mr. Couchman, the Foundation and Xstelos, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
  2. Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
  3. Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
  4. Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.